Moxifloxacin Fresenius Kabi (Moxifloxacin Hydrochloride)

Moxifloxacin is a fluoroquinolone antibacterial used to treat infections caused by susceptible bacteria.

• Community‑acquired bacterial pneumonia: Improves clinical outcomes and resolves infection in adult patients.
• Acute bacterial sinusitis: Reduces sinus inflammation and bacterial load, leading to symptom relief.
• Skin and skin‑structure infections: Achieves bacterial eradication and promotes healing of infected skin lesions.
• Complicated intra‑abdominal infections: Provides effective coverage against mixed aerobic and anaerobic pathogens in severe abdominal infections.

• Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA supercoiling and replication. By binding to the quinolone‑binding site, it prevents the unwinding and resealing of DNA strands, halting bacterial DNA synthesis and transcription, leading to rapid bacterial cell death. The dual targeting of both enzymes broadens its activity against Gram‑positive, Gram‑negative and atypical organisms, and the high intracellular penetration enhances efficacy in tissues such as the lungs and sinuses.

Moxifloxacin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild gastrointestinal upset.
• Diarrhea: loose stools, often self‑limiting.
• Headache: transient cranial discomfort.
• Dizziness: occasional vertigo.
• Elevated liver enzymes: mild, reversible increase in transaminases.
• Photosensitivity: increased skin sensitivity to sunlight.

Serious or Rare Side Effects

• Tendon rupture: risk of tendonitis or rupture, especially in older adults.
• QT interval prolongation: may cause cardiac arrhythmias.
• Severe hypersensitivity reactions: including Stevens‑Johnson syndrome or anaphylaxis.

When using Moxifloxacin, clinicians should consider several precautionary measures to minimize risks.

• Renal impairment: adjust therapy or monitor renal function in patients with reduced clearance.
• Hepatic dysfunction: use with caution in liver disease and monitor liver enzymes.
• QT prolongation risk: avoid in patients with known cardiac arrhythmias or electrolyte disturbances.
• Concomitant fluoroquinolones: avoid concurrent use with other quinolones to prevent additive toxicity.
• Tendon disorders: discontinue promptly if tendon pain or inflammation occurs.
• Store at ambient temperature: keep vials below 25°C, protect from light and moisture, and use within the expiry date.

Moxifloxacin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Antacids containing aluminum or magnesium: reduce absorption; separate administration by at least 2 hours.
• Warfarin: may increase INR and bleeding risk; monitor coagulation parameters closely.
• Cytochrome P450 1A2 inhibitors (e.g., fluvoxamine): increase moxifloxacin plasma levels, heightening toxicity.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase risk of CNS stimulation or seizures.
• Theophylline: potential for increased serum concentrations; monitor for toxicity.
• Corticosteroids: combined use may raise risk of tendon rupture.